INT93965

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 2001
Last Reported 2007
Negated 1
Speculated 0
Reported most in Abstract
Documents 5
Total Number 5
Disease Relevance 1.39
Pain Relevance 2.07

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (Slc6a3) plasma membrane (Slc6a3) transmembrane transport (Slc6a3)
Anatomy Link Frequency
striatum 4
substantia nigra 2
substantia nigra pars compacta 2
Slc6a3 (Mus musculus)
Pain Link Frequency Relevance Heat
Dopamine 25 100.00 Very High Very High Very High
Substantia nigra 6 97.28 Very High Very High Very High
dopamine receptor 1 96.40 Very High Very High Very High
imagery 2 95.12 Very High Very High Very High
monoamine 4 91.08 High High
Eae 1 88.00 High High
Endep 4 85.12 High High
fluoxetine 3 83.76 Quite High
substance P 1 79.08 Quite High
Enkephalin 4 78.44 Quite High
Disease Link Frequency Relevance Heat
Targeted Disruption 9 97.52 Very High Very High Very High
Toxicity 7 76.80 Quite High
Poisoning 2 75.00 Quite High
Hypokinesia 1 67.40 Quite High
Dystonia 2 66.84 Quite High
Parkinson's Disease 2 65.52 Quite High
Disease 1 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Only E was able to prevent loss of DAT binding in the lateral striatum and to attenuate the MA-induced increase in striatal PPE mRNA levels (at 1 or 40 microg).
Negative_regulation (prevent) of DAT Binding (binding) of in striatum
1) Confidence 0.42 Published 2005 Journal Neuroendocrinology Section Abstract Doc Link 16446547 Disease Relevance 0.21 Pain Relevance 0.27
Only E was able to prevent loss of DAT binding in the lateral striatum and to attenuate the MA-induced increase in striatal PPE mRNA levels (at 1 or 40 microg).
Negative_regulation (loss) of DAT Binding (binding) of in striatum
2) Confidence 0.42 Published 2005 Journal Neuroendocrinology Section Abstract Doc Link 16446547 Disease Relevance 0.21 Pain Relevance 0.27
In contrast, autoradiography of striatal [3H]GBR 12935 binding to the dopamine transporter was decreased and the mRNA levels of this transporter, measured by in situ hybridization, remained unchanged in the substantia nigra pars compacta.
Negative_regulation (decreased) of dopamine transporter Binding (binding) of in substantia nigra pars compacta associated with dopamine and substantia nigra
3) Confidence 0.35 Published 2001 Journal Neuroscience Section Abstract Doc Link 11226678 Disease Relevance 0.48 Pain Relevance 0.65
Tamoxifen at 50 microg reduced the methamphetamine effect on striatal dopamine concentration, dopamine transporter specific binding and prevented the increase in preproenkephalin mRNA levels; in the substantia nigra tamoxifen prevented the decrease of dopamine transporter mRNA levels.
Negative_regulation (reduced) of dopamine transporter Binding (binding) of in substantia nigra associated with dopamine and substantia nigra
4) Confidence 0.33 Published 2007 Journal Biochem. Pharmacol. Section Abstract Doc Link 17825264 Disease Relevance 0.22 Pain Relevance 0.62
The scale correlated with the striatal volume reduction (r(2)=0.57) and striatal cell loss (r(2)=0.87) but not with the loss of striatal dopaminergic terminals (dopamine transporter binding).
Neg (not) Negative_regulation (loss) of dopamine transporter Binding (binding) of associated with dopamine
5) Confidence 0.20 Published 2002 Journal Neuroscience Section Abstract Doc Link 12379255 Disease Relevance 0.28 Pain Relevance 0.26

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox